Skip to content

iTBS combined with cTBS cross-sequential treatment versus SNT mode for the treatment of depressed adolescents: a randomized controlled clinical study

iTBS combined with cTBS cross-sequential treatment versus SNT for the treatment of depressed adolescents: a randomized controlled clinical study

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500095740
Enrollment
Unknown
Registered
2025-01-13
Start date
2025-01-15
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive disorders

Interventions

combined iTBS and cTBS cross-sequential group:combined iTBS and cTBS cross-sequential stimulation
SNT group:10 sessions of 1800 pulse iTBS per day, treated for 5 days

Sponsors

Affiliated Kangning Hospital of Ningbo University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1.Age 12-18; 2.meet the diagnostic criteria for depression in the 10th Revision of the International Statistical Classification of Diseases (ICD-10); 3.Total score of HAMD-17 >=17 points; 4.Right-handed; 5.The patient's physical examination, medical history, vital signs, routine blood, urine and stool, liver and kidney function, electrolyte, electrocardiogram, electroencephalogram and other indicators were normaL; 6.After fully understanding the safety of transcranial magnetic stimulation (TMS), willing to actively cooperate with the treatment, and signed by the guardian and the informed consent;

Exclusion criteria

Exclusion criteria: 1. MECT treatment within 6 months prior to enrollment; 2. Those with a history of severe physical illness and depression due to other psychoactive and non-dependent substances; 3. Patients with metallic or electronic instruments placed in their bodies, such as intracranial metallic foreign bodies, cochlear implants, pacemakers and stents, and other metallic foreign bodies; 4. Those at risk for seizures, with previous cranial disease, head trauma, alcoholism, EEG abnormalities, MRI evidence of structural abnormalities in the brain, or a family history of epilepsy; 5. Suicidal ideation; 6. Individuals with psychotic symptoms who require combination therapy with antipsychotic drugs.

Design outcomes

Primary

MeasureTime frame
HAMD-17;

Secondary

MeasureTime frame
Neuropsychometric measures related to cognitive behaviour;anxiety symptom, suicidal ideation, self-reported children's depression inventory;Electrophysiology and blood oxygen index;

Countries

China

Contacts

Public ContactXiaoli Liu

Affiliated Kangning Hospital of Ningbo University

1206207800@qq.com+86 574 26302510

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026